<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Because of the potential <z:e sem="disease" ids="C0235378,C0348754" disease_type="Disease or Syndrome;Injury or Poisoning" abbrv="">hepatotoxicity</z:e> of <z:chebi fb="0" ids="26537">retinoids</z:chebi>, prescription of <z:chebi fb="0" ids="6067">isotretinoin</z:chebi> is always very carefully made in healthy subjects, and prohibited in case of concomitant <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">hepatopathy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> consists of <z:hpo ids='HP_0011010'>chronic</z:hpo>, mild, <z:hpo ids='HP_0008282'>unconjugated hyperbilirubinemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In this syndrome, <z:chebi fb="0" ids="6067">isotretinoin</z:chebi> has been reported twice to be perfectly tolerated, and once even beneficial </plain></SENT>
<SENT sid="3" pm="."><plain>We report here a new case of good tolerance and even improvement of a <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> during <z:chebi fb="0" ids="6067">isotretinoin</z:chebi> therapy </plain></SENT>
<SENT sid="4" pm="."><plain>CASE REPORT: A 17-year-old man with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> presented with a nodulocystic <z:hpo ids='HP_0001061'>acne</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Topical agents had been inefficient, and cyclines bad tolerated </plain></SENT>
<SENT sid="6" pm="."><plain>Thus <z:chebi fb="0" ids="6067">isotretinoin</z:chebi> has been gradually introduced, with a regular monitoring of the liver function </plain></SENT>
<SENT sid="7" pm="."><plain>We observed a steady decrease of the <z:e sem="disease" ids="C0020433" disease_type="Disease or Syndrome" abbrv="">bilirubinemia</z:e> during the course of <z:chebi fb="0" ids="6067">isotretinoin</z:chebi>, and then a reappearance of <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> as soon as posology was diminished and particularly after completion of <z:chebi fb="0" ids="6067">isotretinoin</z:chebi> therapy </plain></SENT>
<SENT sid="8" pm="."><plain>DISCUSSION: A review of the literature finds only very few cases of hepatic injuries caused by <z:chebi fb="0" ids="6067">isotretinoin</z:chebi>, contrary to <z:chebi fb="0" ids="4913">etretinate</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Safety of <z:chebi fb="0" ids="6067">isotretinoin</z:chebi> in <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> was first observed in 1984, but its beneficial effects have only recently been described by Wang et al., and we report here a similar case </plain></SENT>
<SENT sid="10" pm="."><plain>Pharmacological mechanisms remain hypothetic </plain></SENT>
<SENT sid="11" pm="."><plain>However, considering the prevalence of <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> and its usual first expression during postpubertal period, it seems to us interesting for therapeutic practice to know that <z:chebi fb="0" ids="6067">isotretinoin</z:chebi> is not less safe in these patients </plain></SENT>
</text></document>